Apitegromab

Last updated

Apitegromab
Monoclonal antibody
Type ?
Target Promyostatin
Clinical data
Other namesSRK-015
ATC code
  • None
Identifiers
CAS Number
UNII

Apitegromab (SRK-015) is a fully human monoclonal antibody developed to treat spinal muscular atrophy. It works by binding to and inhibiting promyostatin, a precursor to myostatin, which limits the size of skeletal muscle tissue, as well as inactive myostatin. It does not bind to active myostatin, activin A, active BMP9/10 or TGFβ1 that all operate on the activin type 2 receptors. [1] [2] [3]

References

  1. ↑ Barrett D, Bilic S, Chyung Y, Cote SM, Iarrobino R, Kacena K, et al. (2021). "A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy". Advances in Therapy. 38 (6): 3203–3222. doi:10.1007/s12325-021-01757-z. ISSN   0741-238X. PMC   8189951 . PMID   33963971.
  2. ↑ Crawford T, Darras B, Day J, Song G, Nomikos G, Place A, et al. (3 May 2022). "Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (P15-5.005)". Neurology. 98 (18 Supplement). ISSN   0028-3878.
  3. ↑ Crawford T, Place A, Barrett D, Cote S, Nomikos G, Song G, et al. (2021). "Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study". Journal of the Neurological Sciences. 429 118388. doi:10.1016/j.jns.2021.118388. S2CID   238481481.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.